趋化因子 CCL5 免疫亚型在人肝癌中具有预后意义

The immunogenicity of the liver tumor microenvironment is clinically heterogeneous and mysterious. The insight into the role of immune cells including tumor-infiltrating lymphocytes (TILs) and chemokine networks, might enable optimal patient selection for immunotherapy. In this study, we aimed at characterizing the liver cancer immune subtypes linked to chemokines and associating with the patient characteristics and clinical outcomes.

We analyzed the immune cells and chemokine signatures of human liver cancer using GTEx and TCGA profiling of 110 normal liver tissues and 369 liver tumor patients.

We performed hierarchical clustering to the chemokine expression by applying immune cells status to categorize the CCL5-related chemokine in liver tumors. The separation was characterized by dividing the liver tumor patients into CCL5-high and low subtypes.

Our results showed that the high expression of myeloid-derived suppressor cells (MDSCs) is associated with a decrease in effector T cells expressing PRF1 in liver tumor progression.

Our data demonstrated that the CCL5-high subtype significantly improved OS (p = 0. 0379, hazard ratio (HR) 0. 67; 95 % CI 0. 43, 0. 98), DFI (p = 0. 0104, HR 0. 63; 95 % CI 0. 44, 0. 90), PFI (p = 0. 0066, HR 0. 64; 95 % CI 0. 46, 0. 89) and working performance status.

Our findings provide a novel perspective of liver cancer chemokine subtypes linked to immune cells. The therapy that can effectively activate effector T cells and inhibit MDSCs targeting chemokine networks might support the magnitude of TILs in liver tumors. The chemokine signatures in the CCL5-subtype are a valuable resource for future research to identify clinically relevant biomarkers.